137 related articles for article (PubMed ID: 38824918)
1. Pharmacokinetic-guided hydroxyurea to reduce transfusions in Ugandan children with sickle cell anemia: study design of the Alternative Dosing And Prevention of Transfusions (ADAPT) trial.
Power-Hays A; Namazzi R; Kato C; McElhinney KE; Conroy AL; Hume H; John C; O'Hara SM; Stuber SE; Lane A; Latham TS; Opoka RO; Ware RE
Acta Haematol; 2024 Jun; ():. PubMed ID: 38824918
[TBL] [Abstract][Full Text] [Related]
2. Reducing transfusion utilization for children with sickle cell anemia in sub-Saharan Africa with hydroxyurea: Analysis from the phase I/II REACH trial.
Power-Hays A; Tomlinson GA; Tshilolo L; Santos B; Williams TN; Olupot-Olupot P; Smart LR; Aygun B; Lane A; Stuber SE; Latham T; Ware RE
Am J Hematol; 2024 Apr; 99(4):625-632. PubMed ID: 38332651
[TBL] [Abstract][Full Text] [Related]
3. Hydroxyurea Optimization through Precision Study (HOPS): study protocol for a randomized, multicenter trial in children with sickle cell anemia.
Meier ER; Creary SE; Heeney MM; Dong M; Appiah-Kubi AO; Nelson SC; Niss O; Piccone C; Quarmyne MO; Quinn CT; Saving KL; Scott JP; Talati R; Latham TS; Pfeiffer A; Shook LM; Vinks AA; Lane A; McGann PT
Trials; 2020 Nov; 21(1):983. PubMed ID: 33246482
[TBL] [Abstract][Full Text] [Related]
4. Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease.
Estcourt LJ; Kohli R; Hopewell S; Trivella M; Wang WC
Cochrane Database Syst Rev; 2020 Jul; 7(7):CD003146. PubMed ID: 32716555
[TBL] [Abstract][Full Text] [Related]
5. Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease.
Estcourt LJ; Fortin PM; Hopewell S; Trivella M; Wang WC
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD003146. PubMed ID: 28094851
[TBL] [Abstract][Full Text] [Related]
6. Primary prevention of stroke in children with sickle cell anemia in sub-Saharan Africa: rationale and design of phase III randomized clinical trial.
Abdullahi SU; Wudil BJ; Bello-Manga H; Musa AB; Gambo S; Galadanci NA; Aminu H; Tijjani Gaya A; Sanusi S; Tabari MA; Galadanci A; Borodo A; Abba MS; Dambatta AH; Haliru L; Gambo A; Cassell H; Rodeghier M; Ghafuri DL; Covert Greene BV; Neville K; Kassim AA; Kirkham F; Trevathan E; Jordan LC; Aliyu MH; DeBaun MR
Pediatr Hematol Oncol; 2021 Feb; 38(1):49-64. PubMed ID: 33236662
[TBL] [Abstract][Full Text] [Related]
7. Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for young children with sickle cell anemia.
McGann PT; Niss O; Dong M; Marahatta A; Howard TA; Mizuno T; Lane A; Kalfa TA; Malik P; Quinn CT; Ware RE; Vinks AA
Am J Hematol; 2019 Aug; 94(8):871-879. PubMed ID: 31106898
[TBL] [Abstract][Full Text] [Related]
8. Development of a pharmacokinetic-guided dose individualization strategy for hydroxyurea treatment in children with sickle cell anaemia.
Dong M; McGann PT; Mizuno T; Ware RE; Vinks AA
Br J Clin Pharmacol; 2016 Apr; 81(4):742-52. PubMed ID: 26615061
[TBL] [Abstract][Full Text] [Related]
9. Hydroxyurea Therapy for Children With Sickle Cell Anemia in Sub-Saharan Africa: Rationale and Design of the REACH Trial.
McGann PT; Tshilolo L; Santos B; Tomlinson GA; Stuber S; Latham T; Aygun B; Obaro SK; Olupot-Olupot P; Williams TN; Odame I; Ware RE;
Pediatr Blood Cancer; 2016 Jan; 63(1):98-104. PubMed ID: 26275071
[TBL] [Abstract][Full Text] [Related]
10. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia.
Opoka RO; Ndugwa CM; Latham TS; Lane A; Hume HA; Kasirye P; Hodges JS; Ware RE; John CC
Blood; 2017 Dec; 130(24):2585-2593. PubMed ID: 29051184
[TBL] [Abstract][Full Text] [Related]
11. Interventions for preventing silent cerebral infarcts in people with sickle cell disease.
Estcourt LJ; Kimber C; Hopewell S; Trivella M; Doree C; Abboud MR
Cochrane Database Syst Rev; 2020 Apr; 4(4):CD012389. PubMed ID: 32250453
[TBL] [Abstract][Full Text] [Related]
12. Interventions for preventing silent cerebral infarcts in people with sickle cell disease.
Estcourt LJ; Fortin PM; Hopewell S; Trivella M; Doree C; Abboud MR
Cochrane Database Syst Rev; 2017 May; 5(5):CD012389. PubMed ID: 28500860
[TBL] [Abstract][Full Text] [Related]
13. Rationale, Development, and Validation of HdxSim, a Clinical Decision Support Tool for Model-Informed Precision Dosing of Hydroxyurea for Children with Sickle Cell Anemia.
Power-Hays A; Dong M; Punt N; Mizuno T; Smart LR; Vinks AA; Ware RE
Clin Pharmacol Ther; 2023 Nov; ():. PubMed ID: 38018175
[TBL] [Abstract][Full Text] [Related]
14. Hydroxyurea Dose Escalation for Sickle Cell Anemia in Sub-Saharan Africa.
John CC; Opoka RO; Latham TS; Hume HA; Nabaggala C; Kasirye P; Ndugwa CM; Lane A; Ware RE
N Engl J Med; 2020 Jun; 382(26):2524-2533. PubMed ID: 32579813
[TBL] [Abstract][Full Text] [Related]
15. Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan Africa.
Tshilolo L; Tomlinson G; Williams TN; Santos B; Olupot-Olupot P; Lane A; Aygun B; Stuber SE; Latham TS; McGann PT; Ware RE;
N Engl J Med; 2019 Jan; 380(2):121-131. PubMed ID: 30501550
[TBL] [Abstract][Full Text] [Related]
16. Hydroxyurea pharmacokinetics and precision dosing in low-resource settings.
Smart LR; Charles M; McElhinney KE; Dong M; Power-Hays A; Howard T; Vinks AA; Ambrose EE; Ware RE
Front Mol Biosci; 2023; 10():1130206. PubMed ID: 37325474
[No Abstract] [Full Text] [Related]
17. Stroke Avoidance for Children in REpública Dominicana (SACRED): Protocol for a Prospective Study of Stroke Risk and Hydroxyurea Treatment in Sickle Cell Anemia.
Jeste ND; Sánchez LM; Urcuyo GS; Bergés ME; Luden JP; Stuber SE; Latham TS; Mena R; Nieves RM; Ware RE
JMIR Res Protoc; 2017 Jun; 6(6):e107. PubMed ID: 28576754
[TBL] [Abstract][Full Text] [Related]
18. Realizing effectiveness across continents with hydroxyurea: Enrollment and baseline characteristics of the multicenter REACH study in Sub-Saharan Africa.
McGann PT; Williams TN; Olupot-Olupot P; Tomlinson GA; Lane A; Luís Reis da Fonseca J; Kitenge R; Mochamah G; Wabwire H; Stuber S; Howard TA; McElhinney K; Aygun B; Latham T; Santos B; Tshilolo L; Ware RE;
Am J Hematol; 2018 Aug; 93(4):537-545. PubMed ID: 29318647
[TBL] [Abstract][Full Text] [Related]
19. Novel Use of Hydroxyurea in an African Region With Malaria: Protocol for a Randomized Controlled Clinical Trial.
Anyanwu JN; Williams O; Sautter CL; Kasirye P; Hume H; Opoka RO; Latham T; Ndugwa C; Ware RE; John CC
JMIR Res Protoc; 2016 Jun; 5(2):e110. PubMed ID: 27339303
[TBL] [Abstract][Full Text] [Related]
20. Hydroxyurea Therapy for Neurological and Cognitive Protection in Pediatric Sickle Cell Anemia in Uganda (BRAIN SAFE II): Protocol for a single-arm open label trial.
Mboizi V; Nabaggala C; Munube D; Ssenkusu JM; Kasirye P; Kamya S; Kawooya MG; Boehme A; Minja F; Mupere E; Opoka R; Rosano C; Green NS; Idro R
medRxiv; 2024 Jan; ():. PubMed ID: 38260320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
